What are the implications of a positive Cologuard (stool DNA) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What to Do After a Positive Cologuard Test

A positive Cologuard (multitarget stool DNA) test requires diagnostic colonoscopy for definitive evaluation, as approximately 68-73% of positive tests will reveal colorectal neoplasia, including 1-4% with colorectal cancer and 24-27% with advanced adenomas 1, 2, 3.

Immediate Next Step

Proceed directly to colonoscopy - this is non-negotiable. The USPSTF explicitly states that when stool-based tests reveal abnormal results, follow-up with colonoscopy is needed for further evaluation 1. Do not repeat the Cologuard test as the initial response.

What the Colonoscopy Will Likely Find

The positive predictive value varies across studies but consistently shows:

  • Colorectal cancer: 1-4% of positive tests 3, 4, 5
  • Advanced adenomas (≥1cm, high-grade dysplasia, or villous features): 24-27% 2, 3
  • Any neoplasia: 68-73% 3, 5
  • Normal colonoscopy or only hyperplastic polyps: 27-32% (these are "false positives") 4, 5

The most recent community-based data from 2025 showed that among 253 patients with complete colonoscopy data after positive Cologuard, 4% had CRC, 24% had advanced adenomas, and 73% had neither 5.

Critical Quality Requirements for the Colonoscopy

Ensure high-quality colonoscopy with meticulous right colon examination - this is essential because missed lesions are a real concern 6. The colonoscopy must include:

  • Complete examination to the cecum
  • Adequate bowel preparation
  • Sufficient withdrawal time
  • Particular attention to the right colon and transverse colon, where sessile serrated lesions may be missed

If Colonoscopy is Negative

Do NOT pursue upper endoscopy or additional gastrointestinal evaluation unless the patient has specific symptoms or signs suggesting upper GI pathology 2.

The 2023 APAGE-APSDE guidelines explicitly state that evaluation of the upper gastrointestinal tract is not indicated for screening asymptomatic participants with positive mt-sDNA and negative colonoscopy, as the risk of incident aerodigestive cancer is not higher than those with negative mt-sDNA 2. A 5.4-year follow-up study confirmed no increased risk of aerodigestive cancers in this population.

Exception: Consider Repeat Testing in Select Cases

If the colonoscopy is truly negative and the patient had a high-quality examination, consider repeat Cologuard testing in 11-29 months only if:

  • There is clinical suspicion that a lesion was missed
  • The initial colonoscopy quality was suboptimal

A 2018 study found that among patients with persistently positive repeat Cologuard tests, 60% had significant lesions on repeat colonoscopy, including high-grade dysplasia and sessile serrated adenomas 6. However, if the repeat Cologuard is negative, the negative predictive value is 100% 6.

Common Pitfalls to Avoid

  1. Do not order upper endoscopy reflexively - this leads to unnecessary procedures and costs without benefit 2

  2. Do not inappropriately shorten surveillance intervals - if colonoscopy is normal after positive Cologuard, follow standard 10-year rescreening guidelines 3

  3. Ensure the test was appropriately ordered - Cologuard is only approved for average-risk adults aged 45-85 years. It should NOT be used in patients with:

    • Family history of colorectal cancer in first-degree relatives
    • Personal history of inflammatory bowel disease
    • Prior colorectal cancer or adenomas
    • Known genetic syndromes (Lynch syndrome, FAP)

    Studies show 12% of Cologuard orders are "off-label" 7, which is inappropriate.

  4. Recognize the high false-positive rate - approximately 27-32% of positive tests will have normal colonoscopy or only hyperplastic polyps 4, 5. This is inherent to the test's design, which prioritizes sensitivity over specificity.

Surveillance After Findings

Follow standard colonoscopy surveillance guidelines based on what is found:

  • CRC detected: Proceed with oncologic management
  • Advanced adenomas: Repeat colonoscopy in 3 years
  • Non-advanced adenomas: Repeat colonoscopy in 5-10 years depending on number and characteristics
  • Normal colonoscopy: Return to routine screening in 10 years (do not use Cologuard again immediately)

Key Takeaway

The positive Cologuard test has done its job by identifying a high-risk population - nearly 70% will have some form of colorectal neoplasia. The test's 92-94% sensitivity for colorectal cancer 2, 8 means it effectively enriches the colonoscopy population with clinically relevant findings, but the definitive diagnostic test remains colonoscopy.

References

Related Questions

If a patient has a first-degree relative with colorectal cancer, can he undergo Cologuard (stool DNA test) for screening?
Is Cologuard a stool‑based test for colorectal cancer screening?
In an 80-year-old patient, what is the appropriate next step if a fecal immunochemical test (FIT) or Cologuard (multitarget stool DNA test) is positive?
Given a history of colon polyps, can I undergo a Cologuard stool DNA test?
What is the false‑positive rate of Cologuard (multi‑target stool DNA test)?
What oral antidiabetic medications are similar to metformin?
What are the key MRI findings to focus on in a patient with cognitive impairment from a memory‑clinic perspective, given chronic ischemic disease, moderate generalized brain volume loss, medial temporal sclerosis with enlargement of the right temporal horn and a relatively prominent right hippocampal tail, recent post‑ischemic edema, chronic small‑vessel ischemic changes, deep cerebral white‑matter infarcts, an old right lacunar infarct, and chronic thalamic lacunar infarct?
What is the difference between a hyperechoic shadowing focus and a non‑shadowing hyperechoic focus on renal ultrasound for kidney stones?
Why is high-dose vitamin D2 (ergocalciferol) prescribed instead of vitamin D3 (cholecalciferol)?
What is the recommended surveillance strategy for an asymptomatic 4 cm thoracic aortic aneurysm?
What is the prognosis for an 80-year-old male with newly diagnosed prostate cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.